315 related articles for article (PubMed ID: 28664935)
21. BRAF mutation leading to central nervous system rosai-dorfman disease.
Richardson TE; Wachsmann M; Oliver D; Abedin Z; Ye D; Burns DK; Raisanen JM; Greenberg BM; Hatanpaa KJ
Ann Neurol; 2018 Jul; 84(1):147-152. PubMed ID: 30014527
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.
Goyal G; Ravindran A; Young JR; Shah MV; Bennani NN; Patnaik MM; Nowakowski GS; Thanarajasingam G; Habermann TM; Vassallo R; Sher T; Parikh SA; Rech KL; Go RS;
Haematologica; 2020; 105(2):348-357. PubMed ID: 31004029
[TBL] [Abstract][Full Text] [Related]
23. Co-occurrence of Langerhans cell histiocytosis and Rosai-Dorfman disease: possible relationship of two histiocytic disorders in rare cases.
O'Malley DP; Duong A; Barry TS; Chen S; Hibbard MK; Ferry JA; Hasserjian RP; Thompson MA; Richardson MS; Jaffe R; Sidhu JS; Banks PM
Mod Pathol; 2010 Dec; 23(12):1616-23. PubMed ID: 20729813
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.
Geerlinks AV; Abla O
Paediatr Drugs; 2023 Jul; 25(4):399-409. PubMed ID: 37204611
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous Rosai Dorfman disease harboring RET and MAP2K1 mutations, successfully treated with methotrexate.
Konstantinou MP; Tournier E
Int J Dermatol; 2022 Nov; 61(11):1409-1411. PubMed ID: 35569068
[No Abstract] [Full Text] [Related]
26. Clinicopathological and Gene Mutation Analysis of 27 Cases with Extranodal Rosai-Dorfman Disease.
Tang M; Gu XZ; Wu PC; Yang XT
J Inflamm Res; 2022; 15():2775-2787. PubMed ID: 35518839
[TBL] [Abstract][Full Text] [Related]
27. Cyclin D1 expression and novel mutational findings in Rosai-Dorfman disease.
Baraban E; Sadigh S; Rosenbaum J; Van Arnam J; Bogusz AM; Mehr C; Bagg A
Br J Haematol; 2019 Sep; 186(6):837-844. PubMed ID: 31172509
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
[TBL] [Abstract][Full Text] [Related]
29. Rosai-Dorfman Disease between Proliferation and Neoplasia.
Elbaz Younes I; Sokol L; Zhang L
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358690
[TBL] [Abstract][Full Text] [Related]
30. Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status.
Abeykoon JP; Rech KL; Young JR; Ravindran A; Ruan GJ; Dasari S; Morlote DM; King RL; Rummage C; Zanwar S; Acosta-Medina AM; Tobin WO; Shah MV; Bennani NN; Vassallo R; Ryu JH; Koster MJ; Davidge-Pitts CJ; Witzig TE; Goyal G; Go RS;
JAMA Oncol; 2022 Dec; 8(12):1816-1820. PubMed ID: 36201194
[TBL] [Abstract][Full Text] [Related]
31. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
[TBL] [Abstract][Full Text] [Related]
32. CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors.
Xerri L; Adélaïde J; Popovici C; Garnier S; Guille A; Mescam-Mancini L; Laurent C; Brousset P; Coze C; Michel G; Chaffanet M; Bouabdallah R; Coso D; Bertucci F; Birnbaum D
Am J Surg Pathol; 2018 Feb; 42(2):150-159. PubMed ID: 29194093
[TBL] [Abstract][Full Text] [Related]
33. NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study.
Wu KJ; Li SH; Liao JB; Chiou CC; Wu CS; Chen CC
Biology (Basel); 2021 May; 10(5):. PubMed ID: 34063325
[TBL] [Abstract][Full Text] [Related]
34. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
Haroche J; Abla O
Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774
[TBL] [Abstract][Full Text] [Related]
35. MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
Chuang J; Wang C; Guo Y; Valenzuela V; Wu J; Fakih M
Clin Colorectal Cancer; 2021 Mar; 20(1):72-78. PubMed ID: 33436306
[TBL] [Abstract][Full Text] [Related]
36. Histiocytosis.
Rocamora-Blanch G; Climent F; Solanich X
Med Clin (Barc); 2023 Aug; 161(4):166-175. PubMed ID: 37263840
[TBL] [Abstract][Full Text] [Related]
37. The importance of considering monogenic causes of autoimmunity: A somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus.
Ragotte RJ; Dhanrajani A; Pleydell-Pearce J; Del Bel KL; Tarailo-Graovac M; van Karnebeek C; Terry J; Senger C; McKinnon ML; Seear M; Prendiville JS; Tucker LB; Houghton K; Cabral DA; Guzman J; Petty RE; Brown KL; Tekano J; Wu J; Morishita KA; Turvey SE
Clin Immunol; 2017 Feb; 175():143-146. PubMed ID: 28043923
[TBL] [Abstract][Full Text] [Related]
38. Rosai-Dorfman Disease of the Rectum: Newly Identified Genetic Point Mutations and Robotic Resection.
Lambdin J; Phillips JK; Kima ED; Paal E; Nava VE; Duncan J
Am Surg; 2023 Jun; 89(6):2897-2899. PubMed ID: 35187965
[TBL] [Abstract][Full Text] [Related]
39. [Primary intraosseous Rosai-Dorfman disease: a clinicopathological analysis of fourteen cases].
Dong RF; Gong LH; Zhang W; Li L; Sun XQ; Zhang M; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2020 Sep; 49(9):904-909. PubMed ID: 32892555
[No Abstract] [Full Text] [Related]
40. Manifestations of Pediatric Extranodal Rosai Dorfman Disease in the head and neck.
Alwani MM; Elghouche AN; Schueth EA; Campiti VJ; Matt BH; Yekinni AO
Int J Pediatr Otorhinolaryngol; 2020 Apr; 131():109851. PubMed ID: 31901484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
